

ESMO 2023

Highlights from the ASCO congress 2023 for Ribociclib

Ribociclib

Resources related to Ribociclib



Poster
#456P

RIGHT Choice phase II study update

RIGHT Choice phase II study update

QoL analysis from the RIGHT Choice study of 1L RIB+ET vs combination CT in aggressive HR+/HER2- aBC.

See more details

Hide details

Poster
#402P

RIGHT Choice phase II study update

RIGHT Choice phase II study update

1L RIB+ET vs combination CT in aggressive HR+/HER2– aBC: a subgroup analysis of patients with or without visceral crisis

See more details

Hide details

Poster
#409P

Real-world data from the RIBANNA study (Germany) - 5th interim analysis

Real-world data from the RIBANNA study (Germany) - 5th interim analysis

Treatment of elderly patients (>75 years) with first-line ribociclib + endocrine therapy or endocrine monotherapy in clinical routine

See more details

Hide details

Poster
#441P

Real-world data from the RIBANNA study (Germany)

Real-world data from the RIBANNA study (Germany)

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant in subgroups of special interest

See more details

Hide details

Poster
#411P

Real-world data from the RIBANNA study (Germany)

Real-world data from the RIBANNA study (Germany)

Therapy management and safety of first-line ribociclib + aromatase inhibitor/fulvestrant in clinical routine

See more details

Hide details

Image



Ribociclib highlight from an artificial intelligence perspective

It only takes you 3 minutes to get the latest news about the Right Choice trial! Whilst striving for innovation we are piloting a tool using artificial intelligence to deliver a podcast.

[Listen](#)

Abbreviations:

QoL: quality of life; 1L: first-line; RIB: ribociclib; ET: endocrine therapy; CT: chemotherapy; HR+ : hormone receptor positive; HER2– : human epidermal growth factor receptor 2 negative; aBC: advanced breast cancer

Source URL:

<https://www.pro.novartis.com/ch-de/kongresse-und-events/onkologie/esmo-2023>